1-1 of 1
Authors: Shih-Yao Lin
Journal Article
A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 29, Issue Supplement_1, February 2023, Pages S77–S78, https://doi.org/10.1093/ibd/izac247.149
Published: 26 January 2023
